ArticleCell death & disease2023
Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks.
Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Minimally invasive circulating MicroRNA signatures for breast cancer detection and neoadjuvant therapy response prediction in a multicenter MENA cohort.Journal of translational medicine · 2026Article
- Chemotherapy Supports Cancer Cell Dissemination in a Melanoma Preclinical Model.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Comprehensive genomic analysis of non-BRCA familial breast cancer in an Arab population.NPJ breast cancer · 2026Article
- Somatic Mutation Profiling and Therapeutic Landscape of Breast Cancer in the MENA Region.Cells · 2025Article
- Circular RNA profiling identifies circ_0001522, circ_0001278, and circ_0001801 as predictors of unfavorable prognosis and drivers of triple-negative breast cancer hallmarks.Cell death discovery · 2025Article
- LURAP1L-AS1 long noncoding RNA promotes breast cancer progression and associates with poor prognosis.Non-coding RNA research · 2025Article
- The Laterality of Port Catheter Placement in Breast Cancer Patients: Investigating the Impact of Side Selection.Indian journal of surgical oncology · 2025Article
- Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer.Frontiers in bioinformatics · 2025Article
- MicroRNAome profiling of breast cancer unveils hsa-miR-5683 as a tumor suppressor microRNA predicting favorable clinical outcome.Cancer cell international · 2024Article
- Identifying miRNA Signatures Associated with Pancreatic Islet Dysfunction in a FOXA2-Deficient iPSC Model.Stem cell reviews and reports · 2024Article
- Long noncoding RNA profiling unveils LINC00960 as unfavorable prognostic biomarker promoting triple negative breast cancer progression.Cell death discovery · 2024Article
- Therapeutic targeting of the TPX2/TTK network in colorectal cancer.Cell communication and signaling : CCS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that breast cancer (BC) from the Middle East and North Africa (MENA) is presented at younger age with advanced tumor stage, indicating underlying biological differences. Given the scant transcriptomic data on BC from the MENA region and to better understand the biology of this disease, we performed mRNA and microRNA (miRNA) transcriptomic profiling on a local cohort of BC (n = 96) from Qatar. Our data revealed the differentially expressed genes and miRNAs as function of BC molecular subtypes (HR
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.